MSD: Antiviral COVID-19 pill can halve the risk of hospitalisation and death

MSD and Ridgeback Therapeutics announced that their investigational anti-viral medicine reduced the risk of hospitalisation and death by approximately 50% in non-hospitalised adult patients with mild-to-moderate COVID-19.